{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-026020","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2022-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.119676+00:00","generated_at":"2026-06-21T09:43:47.852259+00:00","sec_items":["8.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Nkarta: 70% CR at higher NKX019 doses in NHL; no neurotoxicity observed","bullets":["7 of 10 NHL patients at 1B and 1.5B cell doses achieved complete response (70% CR, 80% ORR) across histologies including LBCL.","No dose-limiting toxicity, ICANS, GvHD, or >Gr3 CRS; safety profile supports outpatient administration.","Durable responses >6 months seen; 5 CRs after one cycle, 3 partial responses deepened to CR with additional cycles.","Dose expansion open: monotherapy in LBCL (CAR T naive/experienced) and combination with rituximab.","Conference call held Dec 5, 2022; NKX019 is an off-the-shelf allogeneic CAR-NK therapy targeting CD19."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-026020","json":"https://secwatch.observer/filing/0000950170-22-026020.json","markdown":"https://secwatch.observer/filing/0000950170-22-026020.md","text":"https://secwatch.observer/filing/0000950170-22-026020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022026020/0000950170-22-026020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022026020/nktx-20221205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T09:43:47.852259+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}